nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—Afatinib—ERBB2—meningioma	0.0306	1	CrCbGaD
Vandetanib—TYRO3—brainstem—meningioma	0.00707	0.025	CbGeAlD
Vandetanib—STK35—brainstem—meningioma	0.00589	0.0208	CbGeAlD
Vandetanib—EPHA5—medulla oblongata—meningioma	0.00493	0.0174	CbGeAlD
Vandetanib—EPHA8—cerebellum—meningioma	0.0045	0.0159	CbGeAlD
Vandetanib—FYN—brainstem—meningioma	0.00449	0.0159	CbGeAlD
Vandetanib—TYRO3—spinal cord—meningioma	0.0044	0.0155	CbGeAlD
Vandetanib—EPHA5—spinal cord—meningioma	0.0044	0.0155	CbGeAlD
Vandetanib—LTK—brain—meningioma	0.00382	0.0135	CbGeAlD
Vandetanib—RIPK2—medulla oblongata—meningioma	0.00379	0.0134	CbGeAlD
Vandetanib—IRAK4—medulla oblongata—meningioma	0.0037	0.0131	CbGeAlD
Vandetanib—EPHA8—brain—meningioma	0.00366	0.0129	CbGeAlD
Vandetanib—MAP2K5—brainstem—meningioma	0.00359	0.0127	CbGeAlD
Vandetanib—EPHA5—cerebellum—meningioma	0.00348	0.0123	CbGeAlD
Vandetanib—TYRO3—cerebellum—meningioma	0.00348	0.0123	CbGeAlD
Vandetanib—BMPR1B—cerebellum—meningioma	0.00341	0.0121	CbGeAlD
Vandetanib—MKNK1—medulla oblongata—meningioma	0.0034	0.012	CbGeAlD
Vandetanib—RIPK2—spinal cord—meningioma	0.00338	0.0119	CbGeAlD
Vandetanib—VEGFA—spinal cord—meningioma	0.00337	0.0119	CbGeAlD
Vandetanib—RET—medulla oblongata—meningioma	0.00336	0.0119	CbGeAlD
Vandetanib—AXL—medulla oblongata—meningioma	0.00335	0.0118	CbGeAlD
Vandetanib—IRAK4—spinal cord—meningioma	0.0033	0.0116	CbGeAlD
Vandetanib—ERBB3—spinal cord—meningioma	0.00323	0.0114	CbGeAlD
Vandetanib—SLK—medulla oblongata—meningioma	0.00322	0.0114	CbGeAlD
Vandetanib—FYN—medulla oblongata—meningioma	0.00313	0.0111	CbGeAlD
Vandetanib—TEK—medulla oblongata—meningioma	0.00306	0.0108	CbGeAlD
Vandetanib—MAP4K5—medulla oblongata—meningioma	0.00306	0.0108	CbGeAlD
Vandetanib—EPHA6—brain—meningioma	0.00305	0.0108	CbGeAlD
Vandetanib—MKNK1—spinal cord—meningioma	0.00303	0.0107	CbGeAlD
Vandetanib—PLK4—brain—meningioma	0.00301	0.0106	CbGeAlD
Vandetanib—RET—spinal cord—meningioma	0.003	0.0106	CbGeAlD
Vandetanib—AXL—spinal cord—meningioma	0.00298	0.0105	CbGeAlD
Vandetanib—FLT3—cerebellum—meningioma	0.00296	0.0105	CbGeAlD
Vandetanib—EPHB6—medulla oblongata—meningioma	0.00293	0.0103	CbGeAlD
Vandetanib—STK35—cerebellum—meningioma	0.0029	0.0103	CbGeAlD
Vandetanib—SLK—spinal cord—meningioma	0.00287	0.0101	CbGeAlD
Vandetanib—EPHA5—brain—meningioma	0.00283	0.01	CbGeAlD
Vandetanib—TYRO3—brain—meningioma	0.00283	0.01	CbGeAlD
Vandetanib—ABL2—cerebellum—meningioma	0.00283	0.00999	CbGeAlD
Vandetanib—YES1—medulla oblongata—meningioma	0.00283	0.00998	CbGeAlD
Vandetanib—LYN—brain—meningioma	0.00282	0.00995	CbGeAlD
Vandetanib—FYN—spinal cord—meningioma	0.00279	0.00987	CbGeAlD
Vandetanib—BMPR1B—brain—meningioma	0.00277	0.00979	CbGeAlD
Vandetanib—MAP3K19—brain—meningioma	0.00277	0.00979	CbGeAlD
Vandetanib—ABL1—brainstem—meningioma	0.00277	0.00978	CbGeAlD
Vandetanib—EGFR—cerebellum—meningioma	0.00276	0.00975	CbGeAlD
Vandetanib—MAP4K5—spinal cord—meningioma	0.00273	0.00964	CbGeAlD
Vandetanib—TEK—spinal cord—meningioma	0.00273	0.00964	CbGeAlD
Vandetanib—RIPK2—cerebellum—meningioma	0.00268	0.00945	CbGeAlD
Vandetanib—VEGFA—cerebellum—meningioma	0.00267	0.00943	CbGeAlD
Vandetanib—IRAK4—cerebellum—meningioma	0.00261	0.00923	CbGeAlD
Vandetanib—EPHB6—spinal cord—meningioma	0.00261	0.00921	CbGeAlD
Vandetanib—ERBB3—cerebellum—meningioma	0.00256	0.00905	CbGeAlD
Vandetanib—YES1—spinal cord—meningioma	0.00252	0.0089	CbGeAlD
Vandetanib—MAP2K5—medulla oblongata—meningioma	0.0025	0.00884	CbGeAlD
Vandetanib—KDR—medulla oblongata—meningioma	0.0025	0.00884	CbGeAlD
Vandetanib—SRC—spinal cord—meningioma	0.00243	0.00857	CbGeAlD
Vandetanib—MKNK1—cerebellum—meningioma	0.00241	0.0085	CbGeAlD
Vandetanib—RET—cerebellum—meningioma	0.00238	0.00839	CbGeAlD
Vandetanib—AXL—cerebellum—meningioma	0.00237	0.00836	CbGeAlD
Vandetanib—STK35—brain—meningioma	0.00236	0.00833	CbGeAlD
Vandetanib—ABL2—brain—meningioma	0.0023	0.00812	CbGeAlD
Vandetanib—SLK—cerebellum—meningioma	0.00228	0.00805	CbGeAlD
Vandetanib—EGFR—brain—meningioma	0.00224	0.00792	CbGeAlD
Vandetanib—KDR—spinal cord—meningioma	0.00223	0.00788	CbGeAlD
Vandetanib—MAP2K5—spinal cord—meningioma	0.00223	0.00788	CbGeAlD
Vandetanib—FYN—cerebellum—meningioma	0.00221	0.00782	CbGeAlD
Vandetanib—FLT4—brain—meningioma	0.00219	0.00772	CbGeAlD
Vandetanib—RIPK2—brain—meningioma	0.00217	0.00768	CbGeAlD
Vandetanib—VEGFA—brain—meningioma	0.00217	0.00766	CbGeAlD
Vandetanib—PDGFRB—medulla oblongata—meningioma	0.00217	0.00765	CbGeAlD
Vandetanib—TEK—cerebellum—meningioma	0.00216	0.00764	CbGeAlD
Vandetanib—MAP4K5—cerebellum—meningioma	0.00216	0.00764	CbGeAlD
Vandetanib—FMO1—brain—meningioma	0.00216	0.00762	CbGeAlD
Vandetanib—IRAK4—brain—meningioma	0.00212	0.0075	CbGeAlD
Vandetanib—ERBB3—brain—meningioma	0.00208	0.00735	CbGeAlD
Vandetanib—EPHB6—cerebellum—meningioma	0.00207	0.00731	CbGeAlD
Vandetanib—YES1—cerebellum—meningioma	0.002	0.00706	CbGeAlD
Vandetanib—STK10—cerebellum—meningioma	0.00198	0.007	CbGeAlD
Vandetanib—MKNK1—brain—meningioma	0.00195	0.0069	CbGeAlD
Vandetanib—PDGFRB—spinal cord—meningioma	0.00193	0.00682	CbGeAlD
Vandetanib—ABL1—medulla oblongata—meningioma	0.00193	0.00682	CbGeAlD
Vandetanib—RET—brain—meningioma	0.00193	0.00682	CbGeAlD
Vandetanib—FGR—brain—meningioma	0.00193	0.00682	CbGeAlD
Vandetanib—SRC—cerebellum—meningioma	0.00192	0.00679	CbGeAlD
Vandetanib—AXL—brain—meningioma	0.00192	0.00679	CbGeAlD
Vandetanib—FMO3—brain—meningioma	0.00186	0.00658	CbGeAlD
Vandetanib—SLK—brain—meningioma	0.00185	0.00653	CbGeAlD
Vandetanib—ORM1—spinal cord—meningioma	0.00181	0.0064	CbGeAlD
Vandetanib—FYN—brain—meningioma	0.0018	0.00635	CbGeAlD
Vandetanib—KDR—cerebellum—meningioma	0.00177	0.00625	CbGeAlD
Vandetanib—MAP2K5—cerebellum—meningioma	0.00177	0.00625	CbGeAlD
Vandetanib—TEK—brain—meningioma	0.00176	0.00621	CbGeAlD
Vandetanib—MAP4K5—brain—meningioma	0.00176	0.00621	CbGeAlD
Vandetanib—ABL1—spinal cord—meningioma	0.00172	0.00608	CbGeAlD
Vandetanib—EPHB6—brain—meningioma	0.00168	0.00593	CbGeAlD
Vandetanib—YES1—brain—meningioma	0.00162	0.00573	CbGeAlD
Vandetanib—STK10—brain—meningioma	0.00161	0.00568	CbGeAlD
Vandetanib—SRC—brain—meningioma	0.00156	0.00552	CbGeAlD
Vandetanib—PDGFRB—cerebellum—meningioma	0.00153	0.00541	CbGeAlD
Vandetanib—MAP2K5—brain—meningioma	0.00144	0.00507	CbGeAlD
Vandetanib—KDR—brain—meningioma	0.00144	0.00507	CbGeAlD
Vandetanib—ABL1—cerebellum—meningioma	0.00136	0.00482	CbGeAlD
Vandetanib—PDGFRB—brain—meningioma	0.00124	0.00439	CbGeAlD
Vandetanib—ABCG2—medulla oblongata—meningioma	0.00122	0.0043	CbGeAlD
Vandetanib—ABL1—brain—meningioma	0.00111	0.00391	CbGeAlD
Vandetanib—ABCG2—spinal cord—meningioma	0.00109	0.00383	CbGeAlD
Vandetanib—ABCC1—cerebellum—meningioma	0.00104	0.00367	CbGeAlD
Vandetanib—ALB—brain—meningioma	0.00102	0.00361	CbGeAlD
Vandetanib—ABCG2—cerebellum—meningioma	0.000861	0.00304	CbGeAlD
Vandetanib—ABCC1—brain—meningioma	0.000844	0.00298	CbGeAlD
Vandetanib—ABCG2—brain—meningioma	0.000699	0.00247	CbGeAlD
Vandetanib—MAP2K5—Signaling Pathways—PDGFB—meningioma	9.71e-05	0.000141	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—ERBB2—meningioma	9.7e-05	0.000141	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—PDGFB—meningioma	9.68e-05	0.000141	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—HES1—meningioma	9.61e-05	0.00014	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling by NGF—AKT1—meningioma	9.59e-05	0.00014	CbGpPWpGaD
Vandetanib—PDGFRB—Innate Immune System—PTEN—meningioma	9.5e-05	0.000138	CbGpPWpGaD
Vandetanib—LYN—Immune System—PDGFB—meningioma	9.47e-05	0.000138	CbGpPWpGaD
Vandetanib—LCK—Platelet activation, signaling and aggregation—AKT1—meningioma	9.46e-05	0.000138	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—PDGFB—meningioma	9.46e-05	0.000138	CbGpPWpGaD
Vandetanib—SRC—Membrane Trafficking—AKT1—meningioma	9.45e-05	0.000138	CbGpPWpGaD
Vandetanib—SRC—Focal Adhesion—AKT1—meningioma	9.45e-05	0.000138	CbGpPWpGaD
Vandetanib—YES1—Hemostasis—TP53—meningioma	9.45e-05	0.000138	CbGpPWpGaD
Vandetanib—ABL1—Immune System—PDGFB—meningioma	9.43e-05	0.000137	CbGpPWpGaD
Vandetanib—SRC—Integrated Pancreatic Cancer Pathway—AKT1—meningioma	9.42e-05	0.000137	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—PTEN—meningioma	9.38e-05	0.000137	CbGpPWpGaD
Vandetanib—KDR—Developmental Biology—AKT1—meningioma	9.37e-05	0.000137	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—PDGFB—meningioma	9.36e-05	0.000136	CbGpPWpGaD
Vandetanib—FYN—Immune System—PDGFB—meningioma	9.33e-05	0.000136	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TSHB—meningioma	9.32e-05	0.000136	CbGpPWpGaD
Vandetanib—LYN—Innate Immune System—PTEN—meningioma	9.3e-05	0.000135	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—SMO—meningioma	9.29e-05	0.000135	CbGpPWpGaD
Vandetanib—RIPK2—Innate Immune System—AKT1—meningioma	9.29e-05	0.000135	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—ERBB2—meningioma	9.27e-05	0.000135	CbGpPWpGaD
Vandetanib—ABL1—Innate Immune System—PTEN—meningioma	9.25e-05	0.000135	CbGpPWpGaD
Vandetanib—FYN—Signaling by NGF—AKT1—meningioma	9.25e-05	0.000135	CbGpPWpGaD
Vandetanib—ABCC1—Disease—HES1—meningioma	9.23e-05	0.000134	CbGpPWpGaD
Vandetanib—FYN—Innate Immune System—PTEN—meningioma	9.15e-05	0.000133	CbGpPWpGaD
Vandetanib—PDGFRB—Adaptive Immune System—PTEN—meningioma	9.12e-05	0.000133	CbGpPWpGaD
Vandetanib—BLK—Immune System—PTEN—meningioma	9.03e-05	0.000132	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—PTEN—meningioma	9.03e-05	0.000132	CbGpPWpGaD
Vandetanib—FGR—Immune System—PTEN—meningioma	9e-05	0.000131	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—ERBB2—meningioma	8.96e-05	0.000131	CbGpPWpGaD
Vandetanib—ERBB3—Disease—ERBB2—meningioma	8.96e-05	0.000131	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—SMO—meningioma	8.96e-05	0.000131	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—ERBB2—meningioma	8.94e-05	0.00013	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—PDGFB—meningioma	8.93e-05	0.00013	CbGpPWpGaD
Vandetanib—LYN—Adaptive Immune System—PTEN—meningioma	8.93e-05	0.00013	CbGpPWpGaD
Vandetanib—RIPK2—Adaptive Immune System—AKT1—meningioma	8.92e-05	0.00013	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—PGR—meningioma	8.91e-05	0.00013	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—ERBB2—meningioma	8.9e-05	0.00013	CbGpPWpGaD
Vandetanib—FGR—Innate Immune System—AKT1—meningioma	8.9e-05	0.00013	CbGpPWpGaD
Vandetanib—AXL—Signaling Pathways—TP53—meningioma	8.89e-05	0.00013	CbGpPWpGaD
Vandetanib—SRC—NGF signalling via TRKA from the plasma membrane—AKT1—meningioma	8.86e-05	0.000129	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—PDGFB—meningioma	8.85e-05	0.000129	CbGpPWpGaD
Vandetanib—FYN—Adaptive Immune System—PTEN—meningioma	8.79e-05	0.000128	CbGpPWpGaD
Vandetanib—EGFR—Disease—HES1—meningioma	8.7e-05	0.000127	CbGpPWpGaD
Vandetanib—FYN—Disease—PDGFB—meningioma	8.61e-05	0.000125	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—PLAU—meningioma	8.59e-05	0.000125	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—PGR—meningioma	8.59e-05	0.000125	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—ERBB2—meningioma	8.58e-05	0.000125	CbGpPWpGaD
Vandetanib—BLK—Adaptive Immune System—AKT1—meningioma	8.58e-05	0.000125	CbGpPWpGaD
Vandetanib—YES1—Immune System—ERBB2—meningioma	8.52e-05	0.000124	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—PDGFB—meningioma	8.5e-05	0.000124	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism of lipids and lipoproteins—PTEN—meningioma	8.48e-05	0.000124	CbGpPWpGaD
Vandetanib—VEGFA—Developmental Biology—AKT1—meningioma	8.42e-05	0.000123	CbGpPWpGaD
Vandetanib—LCK—Disease—HES1—meningioma	8.38e-05	0.000122	CbGpPWpGaD
Vandetanib—SRC—Platelet activation, signaling and aggregation—AKT1—meningioma	8.38e-05	0.000122	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—PTEN—meningioma	8.27e-05	0.000121	CbGpPWpGaD
Vandetanib—VEGFA—Hemostasis—AKT1—meningioma	8.26e-05	0.00012	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—PDGFB—meningioma	8.21e-05	0.00012	CbGpPWpGaD
Vandetanib—ERBB3—Innate Immune System—AKT1—meningioma	8.19e-05	0.000119	CbGpPWpGaD
Vandetanib—FMO3—Metabolism—PTEN—meningioma	8.14e-05	0.000119	CbGpPWpGaD
Vandetanib—YES1—Developmental Biology—AKT1—meningioma	8.14e-05	0.000119	CbGpPWpGaD
Vandetanib—BMPR1B—Signaling Pathways—TP53—meningioma	8.13e-05	0.000118	CbGpPWpGaD
Vandetanib—EGFR—Immune System—PDGFB—meningioma	8.06e-05	0.000117	CbGpPWpGaD
Vandetanib—EGFR—Signaling by NGF—AKT1—meningioma	7.99e-05	0.000116	CbGpPWpGaD
Vandetanib—YES1—Hemostasis—AKT1—meningioma	7.98e-05	0.000116	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—SMO—meningioma	7.93e-05	0.000116	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—ERBB2—meningioma	7.91e-05	0.000115	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—PTEN—meningioma	7.91e-05	0.000115	CbGpPWpGaD
Vandetanib—ABCC1—Disease—PDGFB—meningioma	7.89e-05	0.000115	CbGpPWpGaD
Vandetanib—ERBB3—Adaptive Immune System—AKT1—meningioma	7.86e-05	0.000115	CbGpPWpGaD
Vandetanib—LCK—Immune System—PDGFB—meningioma	7.77e-05	0.000113	CbGpPWpGaD
Vandetanib—LCK—Signaling by NGF—AKT1—meningioma	7.7e-05	0.000112	CbGpPWpGaD
Vandetanib—ERBB3—Disease—PTEN—meningioma	7.64e-05	0.000111	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—PTEN—meningioma	7.62e-05	0.000111	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PGR—meningioma	7.6e-05	0.000111	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—ERBB2—meningioma	7.6e-05	0.000111	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—PTEN—meningioma	7.59e-05	0.000111	CbGpPWpGaD
Vandetanib—ALB—Metabolism—TSHB—meningioma	7.53e-05	0.00011	CbGpPWpGaD
Vandetanib—AXL—Signaling Pathways—AKT1—meningioma	7.51e-05	0.000109	CbGpPWpGaD
Vandetanib—EGFR—Disease—PDGFB—meningioma	7.44e-05	0.000108	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—TP53—meningioma	7.43e-05	0.000108	CbGpPWpGaD
Vandetanib—MKNK1—Disease—AKT1—meningioma	7.43e-05	0.000108	CbGpPWpGaD
Vandetanib—SRC—Disease—HES1—meningioma	7.42e-05	0.000108	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—PTEN—meningioma	7.32e-05	0.000107	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—HES1—meningioma	7.32e-05	0.000107	CbGpPWpGaD
Vandetanib—YES1—Immune System—PTEN—meningioma	7.26e-05	0.000106	CbGpPWpGaD
Vandetanib—YES1—Innate Immune System—AKT1—meningioma	7.19e-05	0.000105	CbGpPWpGaD
Vandetanib—LCK—Disease—PDGFB—meningioma	7.17e-05	0.000104	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—HES1—meningioma	7.16e-05	0.000104	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—ERBB2—meningioma	7.12e-05	0.000104	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—HES1—meningioma	7.05e-05	0.000103	CbGpPWpGaD
Vandetanib—LYN—Hemostasis—TP53—meningioma	7.05e-05	0.000103	CbGpPWpGaD
Vandetanib—ABL1—Hemostasis—TP53—meningioma	7.02e-05	0.000102	CbGpPWpGaD
Vandetanib—FYN—Hemostasis—TP53—meningioma	6.94e-05	0.000101	CbGpPWpGaD
Vandetanib—YES1—Adaptive Immune System—AKT1—meningioma	6.9e-05	0.000101	CbGpPWpGaD
Vandetanib—SRC—Immune System—PDGFB—meningioma	6.87e-05	0.0001	CbGpPWpGaD
Vandetanib—BMPR1B—Signaling Pathways—AKT1—meningioma	6.86e-05	0.0001	CbGpPWpGaD
Vandetanib—SRC—Signaling by NGF—AKT1—meningioma	6.82e-05	9.93e-05	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—PTEN—meningioma	6.75e-05	9.83e-05	CbGpPWpGaD
Vandetanib—FMO1—Metabolism—AKT1—meningioma	6.56e-05	9.56e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—ERBB2—meningioma	6.51e-05	9.48e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—ERBB2—meningioma	6.49e-05	9.45e-05	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—PTEN—meningioma	6.48e-05	9.44e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—ERBB2—meningioma	6.35e-05	9.25e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—PDGFB—meningioma	6.35e-05	9.25e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—ERBB2—meningioma	6.34e-05	9.24e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—ERBB2—meningioma	6.32e-05	9.21e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ALAD—meningioma	6.31e-05	9.19e-05	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—AKT1—meningioma	6.28e-05	9.15e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—ERBB2—meningioma	6.27e-05	9.14e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—PDGFB—meningioma	6.26e-05	9.12e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—ERBB2—meningioma	6.25e-05	9.11e-05	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—TP53—meningioma	6.16e-05	8.98e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—PDGFB—meningioma	6.13e-05	8.93e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—HES1—meningioma	6.09e-05	8.88e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—PTEN—meningioma	6.07e-05	8.84e-05	CbGpPWpGaD
Vandetanib—LYN—Developmental Biology—AKT1—meningioma	6.07e-05	8.84e-05	CbGpPWpGaD
Vandetanib—ABL1—Developmental Biology—AKT1—meningioma	6.04e-05	8.8e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—PDGFB—meningioma	6.03e-05	8.79e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—ERBB2—meningioma	5.99e-05	8.73e-05	CbGpPWpGaD
Vandetanib—IRAK4—Immune System—AKT1—meningioma	5.98e-05	8.71e-05	CbGpPWpGaD
Vandetanib—FYN—Developmental Biology—AKT1—meningioma	5.97e-05	8.7e-05	CbGpPWpGaD
Vandetanib—LYN—Hemostasis—AKT1—meningioma	5.95e-05	8.67e-05	CbGpPWpGaD
Vandetanib—ABL1—Hemostasis—AKT1—meningioma	5.92e-05	8.63e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—HES1—meningioma	5.87e-05	8.55e-05	CbGpPWpGaD
Vandetanib—FYN—Hemostasis—AKT1—meningioma	5.86e-05	8.54e-05	CbGpPWpGaD
Vandetanib—LCK—Hemostasis—TP53—meningioma	5.78e-05	8.42e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—ERBB2—meningioma	5.77e-05	8.41e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—ERBB2—meningioma	5.7e-05	8.31e-05	CbGpPWpGaD
Vandetanib—ALB—Platelet activation, signaling and aggregation—AKT1—meningioma	5.66e-05	8.24e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—PTEN—meningioma	5.55e-05	8.09e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—PTEN—meningioma	5.53e-05	8.06e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—ERBB2—meningioma	5.51e-05	8.02e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Innate Immune System—AKT1—meningioma	5.47e-05	7.97e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—PTEN—meningioma	5.42e-05	7.89e-05	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—AKT1—meningioma	5.41e-05	7.88e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—PTEN—meningioma	5.41e-05	7.88e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—ERBB2—meningioma	5.4e-05	7.87e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—PTEN—meningioma	5.39e-05	7.85e-05	CbGpPWpGaD
Vandetanib—LYN—Innate Immune System—AKT1—meningioma	5.36e-05	7.81e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—PTEN—meningioma	5.35e-05	7.79e-05	CbGpPWpGaD
Vandetanib—ABL1—Innate Immune System—AKT1—meningioma	5.33e-05	7.77e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—PTEN—meningioma	5.33e-05	7.77e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—ERBB2—meningioma	5.29e-05	7.71e-05	CbGpPWpGaD
Vandetanib—FYN—Innate Immune System—AKT1—meningioma	5.28e-05	7.69e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Adaptive Immune System—AKT1—meningioma	5.26e-05	7.66e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—PDGFB—meningioma	5.21e-05	7.59e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—ERBB2—meningioma	5.2e-05	7.58e-05	CbGpPWpGaD
Vandetanib—BLK—Immune System—AKT1—meningioma	5.2e-05	7.58e-05	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—AKT1—meningioma	5.2e-05	7.58e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—HES1—meningioma	5.2e-05	7.57e-05	CbGpPWpGaD
Vandetanib—FGR—Immune System—AKT1—meningioma	5.19e-05	7.56e-05	CbGpPWpGaD
Vandetanib—EGFR—Developmental Biology—AKT1—meningioma	5.16e-05	7.52e-05	CbGpPWpGaD
Vandetanib—LYN—Adaptive Immune System—AKT1—meningioma	5.15e-05	7.5e-05	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—TP53—meningioma	5.11e-05	7.45e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—PTEN—meningioma	5.11e-05	7.44e-05	CbGpPWpGaD
Vandetanib—FYN—Adaptive Immune System—AKT1—meningioma	5.07e-05	7.38e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—PDGFB—meningioma	5.02e-05	7.32e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—ERBB2—meningioma	4.99e-05	7.27e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—PTEN—meningioma	4.92e-05	7.17e-05	CbGpPWpGaD
Vandetanib—LCK—Hemostasis—AKT1—meningioma	4.88e-05	7.11e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—PTEN—meningioma	4.86e-05	7.08e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—ERBB2—meningioma	4.81e-05	7e-05	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—AKT1—meningioma	4.77e-05	6.95e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—PTEN—meningioma	4.7e-05	6.84e-05	CbGpPWpGaD
Vandetanib—FMO3—Metabolism—AKT1—meningioma	4.69e-05	6.84e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—ERBB2—meningioma	4.61e-05	6.71e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism of lipids and lipoproteins—PTEN—meningioma	4.61e-05	6.71e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—PTEN—meningioma	4.61e-05	6.71e-05	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—AKT1—meningioma	4.56e-05	6.64e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—PTEN—meningioma	4.51e-05	6.57e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PDGFB—meningioma	4.44e-05	6.48e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—PTEN—meningioma	4.44e-05	6.47e-05	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—AKT1—meningioma	4.4e-05	6.42e-05	CbGpPWpGaD
Vandetanib—ERBB3—Disease—AKT1—meningioma	4.4e-05	6.41e-05	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—AKT1—meningioma	4.39e-05	6.4e-05	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—AKT1—meningioma	4.38e-05	6.38e-05	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—AKT1—meningioma	4.32e-05	6.29e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—ERBB2—meningioma	4.25e-05	6.2e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—PTEN—meningioma	4.25e-05	6.2e-05	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—AKT1—meningioma	4.22e-05	6.15e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—ERBB2—meningioma	4.19e-05	6.11e-05	CbGpPWpGaD
Vandetanib—YES1—Immune System—AKT1—meningioma	4.19e-05	6.1e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—TP53—meningioma	4.14e-05	6.03e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—ERBB2—meningioma	4.11e-05	5.98e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—PTEN—meningioma	4.1e-05	5.97e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—TSHB—meningioma	4.06e-05	5.92e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—ERBB2—meningioma	4.04e-05	5.89e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—PTEN—meningioma	3.93e-05	5.73e-05	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—AKT1—meningioma	3.89e-05	5.67e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—TP53—meningioma	3.79e-05	5.52e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—PTEN—meningioma	3.78e-05	5.51e-05	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—AKT1—meningioma	3.73e-05	5.44e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—TP53—meningioma	3.69e-05	5.38e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—TP53—meningioma	3.65e-05	5.32e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—PTEN—meningioma	3.63e-05	5.29e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—PTEN—meningioma	3.58e-05	5.21e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—PTEN—meningioma	3.5e-05	5.1e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—AKT1—meningioma	3.5e-05	5.1e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—ERBB2—meningioma	3.49e-05	5.09e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—TP53—meningioma	3.45e-05	5.03e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—PTEN—meningioma	3.45e-05	5.02e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—ERBB2—meningioma	3.37e-05	4.9e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PTEN—meningioma	3.32e-05	4.84e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—TP53—meningioma	3.32e-05	4.83e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—TP53—meningioma	3.2e-05	4.67e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—AKT1—meningioma	3.2e-05	4.66e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—AKT1—meningioma	3.19e-05	4.64e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—AKT1—meningioma	3.12e-05	4.55e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—AKT1—meningioma	3.12e-05	4.54e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—AKT1—meningioma	3.11e-05	4.53e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—AKT1—meningioma	3.08e-05	4.49e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—AKT1—meningioma	3.07e-05	4.48e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—ERBB2—meningioma	2.98e-05	4.34e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—PTEN—meningioma	2.98e-05	4.34e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—AKT1—meningioma	2.94e-05	4.29e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—AKT1—meningioma	2.92e-05	4.25e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—AKT1—meningioma	2.91e-05	4.23e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—PTEN—meningioma	2.87e-05	4.18e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—AKT1—meningioma	2.84e-05	4.13e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—AKT1—meningioma	2.8e-05	4.08e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—AKT1—meningioma	2.71e-05	3.94e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—AKT1—meningioma	2.65e-05	3.87e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—AKT1—meningioma	2.6e-05	3.79e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—AKT1—meningioma	2.56e-05	3.73e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PTEN—meningioma	2.54e-05	3.7e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—AKT1—meningioma	2.45e-05	3.57e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—TP53—meningioma	2.44e-05	3.56e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—TP53—meningioma	2.39e-05	3.48e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—AKT1—meningioma	2.36e-05	3.44e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—TP53—meningioma	2.35e-05	3.43e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—AKT1—meningioma	2.26e-05	3.3e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—AKT1—meningioma	2.18e-05	3.17e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—AKT1—meningioma	2.09e-05	3.05e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—AKT1—meningioma	2.06e-05	3e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PTEN—meningioma	2.05e-05	2.99e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TP53—meningioma	2.03e-05	2.96e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—AKT1—meningioma	2.02e-05	2.94e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—AKT1—meningioma	1.99e-05	2.89e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TP53—meningioma	1.96e-05	2.85e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—AKT1—meningioma	1.92e-05	2.79e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TP53—meningioma	1.73e-05	2.53e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—AKT1—meningioma	1.72e-05	2.5e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—AKT1—meningioma	1.65e-05	2.41e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—AKT1—meningioma	1.46e-05	2.13e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—AKT1—meningioma	1.18e-05	1.72e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PTEN—meningioma	1.11e-05	1.61e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—AKT1—meningioma	6.38e-06	9.3e-06	CbGpPWpGaD
